REPLIMUNE GROUP, INC. Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent
REPLIMUNE GROUP, INC. (REPL) reported Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent of -$314.49 million for the 12-month period ending 2026-03-31, per its 10-K filed 2026-06-29.
Financial Statements › Income Statement › Net Income
us-gaap:IncomeLossFromContinuingOperations · last filed 2026-06-29
- REPLIMUNE GROUP, INC. income (loss) from continuing operations, net of tax, attributable to parent for fiscal 2026 was -$314.49M.
- REPLIMUNE GROUP, INC. income (loss) from continuing operations, net of tax, attributable to parent for fiscal 2025 was -$246.83M.
- REPLIMUNE GROUP, INC. income (loss) from continuing operations, net of tax, attributable to parent for fiscal 2024 was -$215.39M.
- REPLIMUNE GROUP, INC. income (loss) from continuing operations, net of tax, attributable to parent for fiscal 2023 was -$174.00M.
| Period end | Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent 12 month |
|---|---|
| 2026-03-31 | -$314.49M 10-K · filed 2026-06-29 |
| 2025-03-31 | -$246.83M 10-K · filed 2026-06-29 |
| 2024-03-31 | -$215.39M 10-K · filed 2025-05-22 |
| 2023-03-31 | -$174.00M 10-K · filed 2024-05-16 |
| 2022-03-31 | -$118.04M 10-K · filed 2023-05-18 |
| 2021-03-31 | -$80.87M 10-K · filed 2022-05-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B |